Nafaa Fadhel Nafea Alharbi
Biographic Data
| ID | 6954647 |
|---|---|
| NAME | Nafaa Fadhel Nafea Alharbi |
| GIVEN NAMES | Nafaa Fadhel Nafea |
| FAMILY NAME | Alharbi |
| SIGNATURE | ALHARBI N F N |
| AFFILIATIONS | Ministry of Health |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Current Strategies for Improvements in the Treatment of Alzheimer's Disease
There have been many promising developments in recent years. Several new targets have been identified and new drugs developed, or existing drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cognitive function in animal models and in humans but then produced no significant benefit in AD patients in phase 3 trials. Several strate…
Current Strategies for Improvements in the Treatment of Alzheimer's Disease
There have been many promising developments in recent years. Several new targets have been identified and new drugs developed, or existing drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cognitive function in animal models and in humans but then produced no significant benefit in AD patients in phase 3 trials. Several strate…
Current strategies for improvements in the treatment of Alzheimer's disease
There have been many promising developments in recent years. Several new targets have been iden fied and new drugs developed, or exis ng drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cogni ve func on in animal models and in humans but then produced no significant benefit in AD pa ents in phase 3 trials. Several strategies …
No prominent works on this page.
Current Strategies for Improvements in the Treatment of Alzheimer's Disease
There have been many promising developments in recent years. Several new targets have been identified and new drugs developed, or existing drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cognitive function in animal models and in humans but then produced no significant benefit in AD patients in phase 3 trials. Several strate…
Current Strategies for Improvements in the Treatment of Alzheimer's Disease
There have been many promising developments in recent years. Several new targets have been identified and new drugs developed, or existing drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cognitive function in animal models and in humans but then produced no significant benefit in AD patients in phase 3 trials. Several strate…
Current strategies for improvements in the treatment of Alzheimer's disease
There have been many promising developments in recent years. Several new targets have been iden fied and new drugs developed, or exis ng drugs adapted, to treat AD. However, there are problems with side-effects and specificity. A number of drugs have reduced β-amyloid/ phosphorylated tau levels and improved cogni ve func on in animal models and in humans but then produced no significant benefit in AD pa ents in phase 3 trials. Several strategies …
Disease (3 works) · Engineering (3 works) · Health, Environment, Cognitive Aging (3 works) · Medicine (3 works) · Psychology (3 works) · Current (fluid (2 works) · Dementia and Cognitive Impairment Research (2 works) · Electrical engineering (2 works) · Intensive care medicine (2 works) · Internal Medicine (2 works)